VIRI Company Profile and Key Details

VIRI has shown weak momentum, losing -0.77% over the past week and -39.69% over the past quarter, though year-to-date performance is down -73.04%. Short-term trend indicators are bullishly aligned (SMA20 -13.91%, SMA50 -16.96%, SMA200 -53.65%). The stock’s 14-day RSI is 41.02 (neutral), while the ATR of 0.02 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -85.1% below its high and over 23.02% above its low.

Virios Therapeutics, Inc. has 1.33 million shares outstanding. The public float is 1.04 million shares, elevated short interest at 1.76% of float. This equals 18.80 thousand shares. The short ratio is 0.64 days. Institutional investors hold 3.86% of the float. Insiders own 6.74%. Duncan Gregory Scott holds 57.46 thousand shares, Pridgen William has 52.04 thousand shares and Keefer David R has 5.00 thousand shares.

Virios Therapeutics, Inc. generated EPS of -$0.23 over the past year. Five-year average earnings growth is -2.02%. The latest quarter delivered EPS of -$0.06. The next quarter is forecast at -$0.05. Next year's EPS is expected at $27.59. Virios Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended November 11, 2024, missed forecasts by 20.0%. The prior quarter beat by -28.57%. Over the last six quarters, Apple has recorded several small beats. These include 14.29% in August 10, 2023.

Virios Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.18. This means the shares are trading below this model’s fair value.

Virios Therapeutics, Inc. (NASDAQ:VIRI) closed at $0.15 USD, gaining $0.02 (12.40%) from the previous close of $0.14. The stock is currently mid-range between its 52-week high and low $0.14 and $26.00. With a market capitalization of about $206.50 thousand, Virios Therapeutics, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.58). Key stats such as the average daily volume over the past year has been around 87.79 thousand shares, trading with heavier-than-usual volume. Headquartered in Alpharetta, GA, Virios Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Gregory Duncan, the company employs approximately 4 people and listed since December 17, 2020. Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response.

Our AI price prediction model suggests that Virios Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -19.14%, with price expected at $3.59 by November 18, 2024, within a range of $2.24 to $4.87 3-Month Outlook: Projected rise of 9.23%, reaching $4.85 by January 30, 2025, with a range of $3.67 to $6.06. 1-Year Outlook: Projected loss of -95.5%, with price at $0.20 by November 04, 2025, within a range of $0.00 to $1.38.

Virios Therapeutics, Inc. (NASDAQ:VIRI) shares are down -73.04% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Virios Therapeutics, Inc. trading at a premium to the broader market with a P/E of 0.0. Analyst sentiment is mixed, with the majority of ratings in Neutral territory and a mean price target of $3.00, suggesting -32.43% downside. Our AI forecast model points to short-term weakness (-19.14% over two weeks), a medium-term rise (9.23% over three months), and a longer-term loss (-95.5% over one year), with expected trading ranges indicating moderate volatility.

Virios Therapeutics, Inc. trades at a P/E ratio of 0.0, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 0.06 suggesting the stock is closer to book value. The P/FCF stands at -0.0, also below market averages.